



## AMENDMENTS TO THE CLAIMS

**Claims 1 to 42 (cancelled)**

**Claim 43 (previously presented)**

A carbohydrate peptide conjugate selected from the group consisting of the conjugates of the following formulae (a) to (d):



wherein

B is a structurally defined carbohydrate moiety containing a B cell epitope other than a sialoside,

T is a CD4T<sup>+</sup> cell epitope;

K is a lysine residue;

n is an integer from 1 to 9; and

wherein the B and T groups are covalently attached to the poly-lysine carrier.

**Claim 44** (previously presented)

A conjugate of claim 43 wherein the carbohydrate moiety is galactosyl.

**Claim 45** (previously presented)

A conjugate of claim 43 wherein the carbohydrate moiety is galactosyl residue and is substituted by another glycosyl residue.

**Claim 46** (previously presented)

A conjugate of claim 43 wherein the carbohydrate is a tumor antigen.

**Claim 47** (previously presented)

A conjugate of claim 43 wherein the epitope T is the 103:115 peptide of the VPI protein of poliovirus type 1.

**Claim 48** (previously presented)

A conjugate of claim 43 wherein the carbohydrate is grafted in combination with a tumor peptidic CD8<sup>+</sup>T cell epitope.

**Claim 49** (previously presented)

A conjugate of claim 43 wherein the carbohydrate is of bacterial or fungal origin.

**Claim 50** (previously presented)

A conjugate of claim 43 wherein the carbohydrate is from capsular bacterial polysaccharides selected from the group consisting of *Neisseria meningitis*, *Haemophilus influenza*; *Streptococcus pneumonia* and other *Streptococcus* species, with the exception of sialylated polysaccharides.

**Claim 51** (previously presented)

A pharmaceutical composition comprising the conjugate of claim 43 and a pharmaceutical carrier.

**Claim 52** (previously presented)

A pharmaceutical composition comprising the conjugate of claim 43 and a suitable carrier and adjuvant.

**Claim 53** (previously presented)

A vaccine comprising the conjugate of claim 43.

**Claim 54** (previously presented)

An immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 43 capable to elicit an immune response against a viral infection caused by a hepatitis virus, HIV or CMV pathogen.

**Claim 55** (previously presented)

An immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 54 wherein said composition is capable of increasing the survival of tumor bearing human or animal.

**Claim 56** (previously presented)


The immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 54 wherein said conjugate comprises various carbohydrate antigens to induce more efficient anti-tumor immunity against cancers.

**Claim 57** (previously presented)

An immunogenic composition comprising a carbohydrate peptide conjugate of claim 43 in combination with a peptide comprising at least one CTL epitope.

**Claim 58** (currently amended)

A method for enhancing the immune response of a human or animal body to B and/or T-cell responses, wherein ~~the conjugate of claim 43~~ a carbohydrate peptide conjugate selected from the group consisting of the conjugates of the following formulae (a) to (d):



wherein

B is a structurally defined carbohydrate moiety containing a B cell epitope other than a sialoside,

T is a CD4T + cell epitope;

K is a lysine residue;

n is an integer from 1 to 9; and

wherein the B and T groups are covalently attached to the poly-lysine carrier is


administered to said human or animal body in need thereof in an effective amount.

#### **Claim 59 (previously presented)**

A method for enhancing the immune response of a human or animal body to B and/or T-cell responses against bacteria wherein an effective amount of the conjugate of claim 43 is administered to said human or animal body in need thereof.

**Claim 60 (currently amended)**

A method of inducing B-cell responses in a human or animal body wherein an effective amount of ~~the conjugate of claim 43~~ a carbohydrate peptide conjugate selected from the group consisting of the conjugates of the following formulae (a) to (d):



wherein

B is a structurally defined carbohydrate moiety containing a B cell epitope other than a sialoside,

T is a CD4T + cell epitope;

K is a lysine residue;

n is an integer from 1 to 9; and

wherein the B and T groups are covalently attached to the poly-lysine carrier is

administered to said human body in need thereof.

**Claim 61** (previously presented)

A method of vaccination of a human body wherein an effective amount of the conjugate is administered to said human or animal body in need thereof.

**Claim 62** (previously presented)

A method for enhancing a T-CD4<sup>+</sup> immune response against an antigen within a human or animal body, wherein an effective amount of the conjugate of claim 43 is administered to said human or animal body in need thereof.

**Claim 63** (previously presented)

A method for priming a cytotoxic T-cell response in a human or animal body, wherein an effective amount of the conjugate of claim 46 comprising at least one CTL epitope is administered to said human or animal body in need thereof.